NOS1AP基因多态性对瑞舒伐他汀钙调脂效果的影响
x

请在关注微信后,向客服人员索取文件

篇名: NOS1AP基因多态性对瑞舒伐他汀钙调脂效果的影响
TITLE:
摘要: 目的:探讨一氧化氮合酶1转接蛋白(NOS1AP)基因rs12742393位点A/C多态性对瑞舒伐他汀钙调脂效果的影响。方法:选取2014年1月-2015年6月于我院心内科接受治疗的冠心病患者236例,予瑞舒伐他汀钙等对症治疗12周。采用聚合酶链反应-限制性片段长度多态性分析法检测各患者NOS1AP基因rs12742393位点A/C多态性,采用光电比色法分别于治疗前和治疗后第4、12周检测其血清三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)水平,分析患者基因型与血脂水平变化的相关性。结果:236例冠心病患者中,AA、AC、CC基因型分别有131(55.5%)、98(41.5%)和7例(3.0%),各基因型和等位基因频率均符合Hardy-Weinberg平衡(P>0.05);血脂正常患者132例,合并高脂血症患者104例,两者各基因型和等位基因型频率比较,差异均有统计学意义(P<0.05)。104例冠心病合并高脂血症患者在治疗前,AA与AC+CC基因型患者TG、TC、LDL-C和HDL-C水平比较,差异均无统计学意义(P>0.05)。治疗后第4、12周,各基因型患者TG、TC和LDL-C水平均较治疗前显著降低;治疗后第4周,AC+CC基因型患者LDL-C水平显著低于AA基因型患者,且较治疗前的变化幅度显著大于AA基因型患者,差异均有统计学意义(P<0.05);各基因型患者HDL-C水平与治疗前比较,治疗后第4、12周AA基因型患者TG、TC、HLD-C水平及其较治疗前的变化幅度与AC+CC基因型患者比较,以及治疗后第12周AA基因型患者LDL-C水平及其较治疗前的变化幅度与AC+CC基因型患者比较,差异均无统计学意义(P>0.05)。结论:NOS1AP基因rs12742393位点A/C多态性与冠心病患者合并高脂血症有关,该位点C等位基因可能通过影响LDL-C水平来增强冠心病合并高脂血症患者对瑞舒伐他汀钙调脂效果的反应性。
ABSTRACT: OBJECTIVE: To investigate the effects of NOS1AP rs12742393 A/C gene polymorphism on lipid-regulating response of rosuvastatin calcium. METHODS: Two hundred and thirty six patients with coronary heart disease (CHD) were selected from cardiology department of our hospital during Jan. 2014-Jun. 2015, and then given rosuvastatin calcium and other symptomatic treatment for 12 weeks. Polymorphism of NOS1AP rs12742393 A/C was detected by PCR-RFLP. The serum levels of TG, TC, HDL-C and LDL-C were detected by photoelectric colorimetry before treatment and 4, 12 weeks after treatment. The serum serum relationship of genotype with the level of blood lipid was analyzed. RESULTS: Among 236 CHD patients, there were 131 cases of AA genotype(55.5%), 98 cases of AC genotype(41.5%) and 7 cases of CC genotype(3.0%); genotype and allele frequencies met the Hardy-Weinberg balance (P>0.05). There were 132 patients with normal blood lipid and 104 patients with hypercholesterolemia; there was statistical significance in genotype and allele frequencies (P<0.05). Among 104 CHD patients with hypercholesterolemia before treatment, there was no statistical significance in the levels of TG, TC, LDL-C and HDL-C between AA genotype and AC+CC genotype (P>0.05). 4th and 12th week after treatment, the levels of TG, TC and LDL-C in different genotypes were all decreased significantly; 4th week after treatment, the level of LDL-C in AC+CC genotype was significantly lower than AA genotype, and the change compared to before treatment was significantly more than AA genotype, with statistical significance (P<0.05). There was no statistical significance in the level of HDL-C among different genotypes compared to before treatment; there was no statistical significance in the levels of TG, TC and HDL-C 4th, 12th week after treatment and their changes compared to before treatment between AA genotype and AC+CC genotype; there was no statistical significance in the level of LDL-C 12th week after treatment and their changes between AA genotype and AC+CC genotype(P>0.05). CONCLUSIONS: NOS1AP rs12742393 A/C gene polymorphism is associated with CHD complicated with hypercholesterolemia; the C allele of NOS1AP rs12742393 may strengthen the response of CHD patients with hypercholesterolemia to rosuvastatin calcium through influencing the level of LDL-C.
期刊: 2017年第28卷第5期
作者: 宋金方,赵懿清,葛重宇,高秋芳,朱君
AUTHORS: SONG Jinfang,ZHAO Yiqing,GE Chongyu,GAO Qiufang,ZHU Jun
关键字: 冠心病;基因多态性;NOS1AP基因;瑞舒伐他汀钙;调脂
KEYWORDS: Coronary heart disease; Gene polymorphism; NOS1AP gene; Rosuvastatin calcium; Lipid-regulating
阅读数: 372 次
本月下载数: 4 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!